These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 21326835)

  • 1. Investigating the importance of charged residues in lantibiotics.
    Suda S; Hill C; Cotter PD; Ross RP
    Bioeng Bugs; 2010; 1(5):345-51. PubMed ID: 21326835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioengineering of the model lantibiotic nisin.
    Field D; Cotter PD; Ross RP; Hill C
    Bioengineered; 2015; 6(4):187-92. PubMed ID: 25970137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manipulation of charged residues within the two-peptide lantibiotic lacticin 3147.
    Deegan LH; Suda S; Lawton EM; Draper LA; Hugenholtz F; Peschel A; Hill C; Cotter PD; Ross RP
    Microb Biotechnol; 2010 Mar; 3(2):222-34. PubMed ID: 21255322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The biology of lantibiotics from the lacticin 481 group is coming of age.
    Dufour A; Hindré T; Haras D; Le Pennec JP
    FEMS Microbiol Rev; 2007 Mar; 31(2):134-67. PubMed ID: 17096664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A system for the random mutagenesis of the two-peptide lantibiotic lacticin 3147: analysis of mutants producing reduced antibacterial activities.
    Field D; Collins B; Cotter PD; Hill C; Ross RP
    J Mol Microbiol Biotechnol; 2007; 13(4):226-34. PubMed ID: 17827973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lantibiotics: mode of action, biosynthesis and bioengineering.
    Bierbaum G; Sahl HG
    Curr Pharm Biotechnol; 2009 Jan; 10(1):2-18. PubMed ID: 19149587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of lantibiotic biosynthetic machinery promiscuity and its impact on antimicrobial discovery.
    Sandiford SK
    Expert Opin Drug Discov; 2020 Mar; 15(3):373-382. PubMed ID: 31941374
    [No Abstract]   [Full Text] [Related]  

  • 8. Modifying the Lantibiotic Mutacin 1140 for Increased Yield, Activity, and Stability.
    Geng M; Smith L
    Appl Environ Microbiol; 2018 Aug; 84(15):. PubMed ID: 29776930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formicin - a novel broad-spectrum two-component lantibiotic produced by Bacillus paralicheniformis APC 1576.
    Collins FWJ; O'Connor PM; O'Sullivan O; Rea MC; Hill C; Ross RP
    Microbiology (Reading); 2016 Sep; 162(9):1662-1671. PubMed ID: 27450592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical synthesis of the lantibiotic lacticin 481 reveals the importance of lanthionine stereochemistry.
    Knerr PJ; van der Donk WA
    J Am Chem Soc; 2013 May; 135(19):7094-7. PubMed ID: 23621626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lacticin 3147--biosynthesis, molecular analysis, immunity, bioengineering and applications.
    Suda S; Cotter PD; Hill C; Ross RP
    Curr Protein Pept Sci; 2012 May; 13(3):193-204. PubMed ID: 21827422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-peptide lantibiotics: a medical perspective.
    Lawton EM; Ross RP; Hill C; Cotter PD
    Mini Rev Med Chem; 2007 Dec; 7(12):1236-47. PubMed ID: 18220976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for the isolation and characterization of antibacterial lantibiotics.
    Jabes D; Donadio S
    Methods Mol Biol; 2010; 618():31-45. PubMed ID: 20094856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing the Antimicrobial Activity of Nisin-Based Lantibiotics against Gram-Negative Pathogens.
    Li Q; Montalban-Lopez M; Kuipers OP
    Appl Environ Microbiol; 2018 Jun; 84(12):. PubMed ID: 29625984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics.
    Smith L; Hillman J
    Curr Opin Microbiol; 2008 Oct; 11(5):401-8. PubMed ID: 18848642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of Gut-Derived Nisin-like Lantibiotics against Human Gut Pathogens and Commensals.
    Zhang ZJ; Wu C; Moreira R; Dorantes D; Pappas T; Sundararajan A; Lin H; Pamer EG; van der Donk WA
    ACS Chem Biol; 2024 Feb; 19(2):357-369. PubMed ID: 38293740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The structure of the lantibiotic lacticin 481 produced by Lactococcus lactis: location of the thioether bridges.
    van den Hooven HW; Lagerwerf FM; Heerma W; Haverkamp J; Piard JC; Hilbers CW; Siezen RJ; Kuipers OP; Rollema HS
    FEBS Lett; 1996 Aug; 391(3):317-22. PubMed ID: 8764998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lantibiotics: structure, biosynthesis and mode of action.
    McAuliffe O; Ross RP; Hill C
    FEMS Microbiol Rev; 2001 May; 25(3):285-308. PubMed ID: 11348686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial mechanism of lantibiotics.
    Islam MR; Nagao J; Zendo T; Sonomoto K
    Biochem Soc Trans; 2012 Dec; 40(6):1528-33. PubMed ID: 23176511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type AII lantibiotic bovicin HJ50 with a rare disulfide bond: structure, structure-activity relationships and mode of action.
    Zhang J; Feng Y; Teng K; Lin Y; Gao Y; Wang J; Zhong J
    Biochem J; 2014 Aug; 461(3):497-508. PubMed ID: 24814218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.